Imunon, Inc. (0HUZ.L)
USD 0.88
(-5.44%)
USD 0.88
(-5.44%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -19.51 Million USD | 45.64% |
| 2022 | -35.89 Million USD | -72.84% |
| 2021 | -20.76 Million USD | 3.32% |
| 2020 | -21.48 Million USD | -27.49% |
| 2019 | -16.85 Million USD | -41.81% |
| 2018 | -11.88 Million USD | 42.72% |
| 2017 | -20.74 Million USD | 5.92% |
| 2016 | -22.05 Million USD | 1.81% |
| 2015 | -22.46 Million USD | 11.9% |
| 2014 | -25.49 Million USD | -98.36% |
| 2013 | -12.85 Million USD | 51.62% |
| 2012 | -26.56 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.78 Million USD | 2.87% |
| 2024 Q1 | -4.92 Million USD | -0.85% |
| 2023 Q3 | -3.47 Million USD | 37.46% |
| 2023 FY | -19.51 Million USD | 45.64% |
| 2023 Q4 | -4.88 Million USD | -40.6% |
| 2023 Q1 | -5.59 Million USD | 57.75% |
| 2023 Q2 | -5.55 Million USD | 0.58% |
| 2022 Q3 | -6.14 Million USD | -1.74% |
| 2022 FY | -35.89 Million USD | -72.84% |
| 2022 Q4 | -13.23 Million USD | -115.23% |
| 2022 Q2 | -6.04 Million USD | 42.31% |
| 2022 Q1 | -10.47 Million USD | -148.13% |
| 2021 Q1 | -5.68 Million USD | -88.87% |
| 2021 FY | -20.76 Million USD | 3.32% |
| 2021 Q2 | -5.44 Million USD | 4.23% |
| 2021 Q4 | -4.22 Million USD | 21.98% |
| 2021 Q3 | -5.41 Million USD | 0.69% |
| 2020 Q3 | -8.07 Million USD | -51.07% |
| 2020 Q4 | -3.01 Million USD | 62.68% |
| 2020 FY | -21.48 Million USD | -27.49% |
| 2020 Q2 | -5.34 Million USD | -5.66% |
| 2020 Q1 | -5.05 Million USD | -62.98% |
| 2019 Q3 | -5.47 Million USD | 7.24% |
| 2019 Q1 | -2.36 Million USD | -143.2% |
| 2019 FY | -16.85 Million USD | -41.81% |
| 2019 Q4 | -3.1 Million USD | 43.35% |
| 2019 Q2 | -5.9 Million USD | -149.4% |
| 2018 Q2 | -8.23 Million USD | -83.84% |
| 2018 Q1 | -4.47 Million USD | 4.35% |
| 2018 FY | -11.88 Million USD | 42.72% |
| 2018 Q4 | 5.48 Million USD | 217.7% |
| 2018 Q3 | -4.65 Million USD | 43.43% |
| 2017 Q4 | -4.68 Million USD | 17.46% |
| 2017 FY | -20.74 Million USD | 5.92% |
| 2017 Q3 | -5.67 Million USD | -8.32% |
| 2017 Q2 | -5.23 Million USD | -1.46% |
| 2017 Q1 | -5.16 Million USD | 4.38% |
| 2016 Q4 | -5.39 Million USD | 15.81% |
| 2016 Q2 | -4.53 Million USD | 20.74% |
| 2016 FY | -22.05 Million USD | 1.81% |
| 2016 Q1 | -5.71 Million USD | -3.67% |
| 2016 Q3 | -6.4 Million USD | -41.46% |
| 2015 Q4 | -5.51 Million USD | -29.21% |
| 2015 Q3 | -4.26 Million USD | 24.8% |
| 2015 Q2 | -5.67 Million USD | 18.99% |
| 2015 Q1 | -7 Million USD | -8.51% |
| 2015 FY | -22.46 Million USD | 11.9% |
| 2014 Q3 | -6.94 Million USD | -4.03% |
| 2014 Q4 | -6.45 Million USD | 7.01% |
| 2014 FY | -25.49 Million USD | -98.36% |
| 2014 Q2 | -6.67 Million USD | -23.06% |
| 2014 Q1 | -5.42 Million USD | -37.29% |
| 2013 Q1 | -5.25 Million USD | 36.41% |
| 2013 Q3 | -4.07 Million USD | -1067.37% |
| 2013 Q4 | -3.94 Million USD | 2.99% |
| 2013 FY | -12.85 Million USD | 51.62% |
| 2013 Q2 | 420.88 Thousand USD | 108.01% |
| 2012 Q4 | -8.25 Million USD | 0.0% |
| 2012 FY | -26.56 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 100.326% |
| Dynavax Technologies Corporation | -6.38 Million USD | -205.447% |
| Illumina, Inc. | -1.16 Billion USD | 98.319% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 101.437% |
| Biogen Inc. | 1.16 Billion USD | 101.681% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 95.605% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 102.474% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 96.359% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 1582.901% |
| Waters Corporation | 642.23 Million USD | 103.039% |
| Perrigo Company plc | -12.7 Million USD | -53.661% |
| uniQure N.V. | -308.47 Million USD | 93.674% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 94.457% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 87.126% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 92.933% |
| bluebird bio, Inc. | -211.91 Million USD | 90.791% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 83.533% |
| Myriad Genetics, Inc. | -112 Million USD | 82.576% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 107.815% |
| Nektar Therapeutics | -276.05 Million USD | 92.931% |
| Editas Medicine, Inc. | -153.21 Million USD | 87.263% |
| Verastem, Inc. | -87.36 Million USD | 77.663% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 99.774% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 56.248% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 82.349% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 51.041% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 111.641% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 92.431% |
| Evolus, Inc. | -61.68 Million USD | 68.363% |
| Adicet Bio, Inc. | -142.65 Million USD | 86.32% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 77.944% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 100.494% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 90.674% |
| FibroGen, Inc. | -284.23 Million USD | 93.134% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 101.574% |
| OPKO Health, Inc. | -188.86 Million USD | 89.667% |
| Homology Medicines, Inc. | -53.74 Million USD | 63.688% |
| Geron Corporation | -184.12 Million USD | 89.401% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 95.567% |
| Exelixis, Inc. | 207.76 Million USD | 109.393% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 77.28% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 58.92% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 95.944% |
| Zoetis Inc. | 2.34 Billion USD | 100.833% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 91.843% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 63.987% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 100.539% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 53.755% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 94.672% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 118.386% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 106.93% |
| Blueprint Medicines Corporation | -506.98 Million USD | 96.151% |
| Insmed Incorporated | -749.56 Million USD | 97.396% |
| TG Therapeutics, Inc. | 12.67 Million USD | 254.001% |
| Incyte Corporation | 597.59 Million USD | 103.266% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 97.434% |